Please Wait.....
Report
In Vitro Diagnostics Market By Product and Services (Reagents and Kits, Instruments, Software and Services), By Technique (Immunodiagnostics, Hematology, Molecular Diagnostics, Tissue Diagnostics, Clinical Chemistry, Others), By Application (Infectious Diseases, Cancer, Cardiac Diseases, Immune System Disorders, Nephrological Diseases, Gastrointestinal Diseases, Others), By End User (Standalone Laboratories, Hospitals, Academic and Medical Schools, Point of Care, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032
Market Report I 2023-10-01 I 391 Pages I Allied Market Research
The in vitro diagnostics market was valued at $92.5billion in 2022 and is estimated to reach $138.4billion by 2032, exhibiting a CAGR of 4.1% from 2023 to 2032.In vitro diagnostics (IVDs) are tests that detect diseases, conditions, and infections. In vitro means these tests are typically conducted in test tubes and similar equipment, as opposed to in vivo tests, which are conducted in the body itself. In vitro diagnostics (IVD) includes a wide range of tools and techniques, including reagents, instruments, software, and services utilized for the examination of specimens such as blood, urine, stool, tissues, and various human body fluids. These diagnostic tools are essential for detecting diseases, conditions, and infections. IVD tests are conducted in various settings, including standalone laboratories, hospital-based facilities, and point of care centers.
In addition, in vitro diagnostic techniques encompass a broad array of methodologies, including clinical chemistry, tissue diagnostics, immunodiagnostics, hematology, and more. For instance, a thyroid function test involves the collection of blood from a patient, which is then analyzed to determine the level of thyroid-stimulating hormone (TSH) in the bloodstream. This test serves as a critical tool in assessing thyroid function. Furthermore, techniques such as polymerase chain reaction (PCR) are employed to identify the presence of infectious diseases such as HIV, hepatitis, and various others. The in vitro diagnostics market growth is significantly driven by increase in the prevalence of chronic diseases such as cardiovascular disorders, cancer, and infectious diseases, surge in awareness about importance of early disease diagnosis, and increase in new test launches, thus fueling the demand for IVD tests for early detection, monitoring, and management. For instance, according to American Cancer Society (ACS), about 1.9 million new cancer cases are expected to be diagnosed in the U.S. in 2023. Thus, rise in prevalence of chronic diseases drives the demand for in vitro diagnostic tests.
In addition, surge in awareness about early disease diagnosis among the general population has increased the demand for in vitro diagnostics. Awareness campaigns, educational seminars, and training programs emphasize the importance of early disease diagnosis. For instance, F. Hoffmann-La Roche Ltd., supports local community partners to run screening programs and counselling programs for diseases such as cancers, hepatitis, tuberculosis, HIV, HPV, and cardiovascular disease.Moreover, ongoing innovations in IVD products, service designs, and technology have prompted doctors and researchers to transition their emphasis away from conventional diagnostic approaches toward personalized medicine. This shift reflects a growing recognition of the benefits of tailoring medical treatments and interventions to individual patient needs and characteristics, which support the market growth.
However, lack of skilled laboratory technicians is anticipated to hinder the market growth during the forecast period. However, rise in the number of diagnostic testing and technological advancements in DNA sequencing are expected to create lucrative opportunities for the market growth during the forecast period.
The in vitro diagnostics market is segmented into product & services, technique, application, end user, and region. By product & services, the market is categorized into reagents & kits, instruments, and software & services.
By technique, the market is divided into immunodiagnostics, hematology, molecular diagnostics, tissue diagnostics, clinical chemistry, and others. By application, the market is classified into infectious diseases, cancer, cardiac diseases, immune system disorders, nephrological diseases, gastrointestinal diseases, and others. By end user, the market is classified into standalone laboratories, hospitals, academic and medical schools, point of care, and others. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major key players that operate in the global in vitro diagnostics market are Freenome Holdings, Inc., Invitae Corporation, Natera, Inc., Agilent Technologies, Inc., Exact Sciences Corporation, Guardant Health, Illumina, Inc., InterVenn Biosciences, NeoGenomics Laboratories, F. Hoffmann-La Roche Ltd., and Thermo Fisher Scientific, Inc. Key players operating in the market have adopted product launch, acquisition, partnership, product approval, and expansion as key strategies to expand their market share and product portfolio.
Key Benefits for Stakeholders
-This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the in vitro diagnostics market analysis from 2022 to 2032 to identify the prevailing in vitro diagnostics market opportunities.
-The market research is offered along with information related to key drivers, restraints, and opportunities.
-Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
-In-depth analysis of the in vitro diagnostics market segmentation assists to determine the prevailing market opportunities.
-Major countries in each region are mapped according to their revenue contribution to the global market.
-Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
-The report includes the analysis of the regional as well as global in vitro diagnostics market trends, key players, market segments, application areas, and market growth strategies.
Additional benefits you will get with this purchase are:
- Quarterly Update and* (only available with a corporate license, on listed price)
- 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
- Free Upcoming Version on the Purchase of Five and Enterprise User License.
- 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
- 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
- Free data Pack on the Five and Enterprise User License. (Excel version of the report)
- Free Updated report if the report is 6-12 months old or older.
- 24-hour priority response*
- Free Industry updates and white papers.
Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
- Regulatory Guidelines
- Additional company profiles with specific to client's interest
- Additional country or region analysis- market size and forecast
- Expanded list for Company Profiles
- Historic market data
- SWOT Analysis
Key Market Segments
By End User
- Standalone Laboratories
- Hospitals
- Academic and Medical Schools
- Point of Care
- Others
By Product and Services
- Reagents and Kits
- Instruments
- Software and Services
By Technique
- Molecular Diagnostics
- Tissue Diagnostics
- Clinical Chemistry
- Others
- Immunodiagnostics
- Hematology
By Application
- Infectious Diseases
- Cancer
- Cardiac Diseases
- Immune System Disorders
- Nephrological Diseases
- Gastrointestinal Diseases
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
- Key Market Players
- InterVenn Biosciences
- Agilent Technologies, Inc.
- Illumina, Inc.
- Thermo Fisher Scientific, Inc.
- NeoGenomics Laboratories
- Exact Sciences Corporation
- Freenome Holdings, Inc.
- Natera, Inc.
- F. Hoffmann-La Roche Ltd.
- Guardant Health
- Invitae Corporation
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter's five forces analysis
3.3.1. Moderate bargaining power of suppliers
3.3.2. Moderate threat of new entrants
3.3.3. Moderate threat of substitutes
3.3.4. Moderate intensity of rivalry
3.3.5. High bargaining power of buyers
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Increase in prevalence of chronic and infectious diseases
3.4.1.2. Surge in awareness about early disease diagnosis and personalized medicine
3.4.1.3. Rise in number of diagnostic laboratories
3.4.2. Restraints
3.4.2.1. Stringent regulatory policies
3.4.3. Opportunities
3.4.3.1. Technological advancements in IVD
CHAPTER 4: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT AND SERVICES
4.1. Overview
4.1.1. Market size and forecast
4.2. Reagents and Kits
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Instruments
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Software and Services
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
CHAPTER 5: IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE
5.1. Overview
5.1.1. Market size and forecast
5.2. Immunodiagnostics
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Hematology
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Molecular Diagnostics
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
5.5. Tissue Diagnostics
5.5.1. Key market trends, growth factors and opportunities
5.5.2. Market size and forecast, by region
5.5.3. Market share analysis by country
5.6. Clinical Chemistry
5.6.1. Key market trends, growth factors and opportunities
5.6.2. Market size and forecast, by region
5.6.3. Market share analysis by country
5.7. Others
5.7.1. Key market trends, growth factors and opportunities
5.7.2. Market size and forecast, by region
5.7.3. Market share analysis by country
CHAPTER 6: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION
6.1. Overview
6.1.1. Market size and forecast
6.2. Infectious Diseases
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Cancer
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Cardiac Diseases
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
6.5. Immune System Disorders
6.5.1. Key market trends, growth factors and opportunities
6.5.2. Market size and forecast, by region
6.5.3. Market share analysis by country
6.6. Nephrological Diseases
6.6.1. Key market trends, growth factors and opportunities
6.6.2. Market size and forecast, by region
6.6.3. Market share analysis by country
6.7. Gastrointestinal Diseases
6.7.1. Key market trends, growth factors and opportunities
6.7.2. Market size and forecast, by region
6.7.3. Market share analysis by country
6.8. Others
6.8.1. Key market trends, growth factors and opportunities
6.8.2. Market size and forecast, by region
6.8.3. Market share analysis by country
CHAPTER 7: IN VITRO DIAGNOSTICS MARKET, BY END USER
7.1. Overview
7.1.1. Market size and forecast
7.2. Standalone Laboratories
7.2.1. Key market trends, growth factors and opportunities
7.2.2. Market size and forecast, by region
7.2.3. Market share analysis by country
7.3. Hospitals
7.3.1. Key market trends, growth factors and opportunities
7.3.2. Market size and forecast, by region
7.3.3. Market share analysis by country
7.4. Academic and Medical Schools
7.4.1. Key market trends, growth factors and opportunities
7.4.2. Market size and forecast, by region
7.4.3. Market share analysis by country
7.5. Point of Care
7.5.1. Key market trends, growth factors and opportunities
7.5.2. Market size and forecast, by region
7.5.3. Market share analysis by country
7.6. Others
7.6.1. Key market trends, growth factors and opportunities
7.6.2. Market size and forecast, by region
7.6.3. Market share analysis by country
CHAPTER 8: IN VITRO DIAGNOSTICS MARKET, BY REGION
8.1. Overview
8.1.1. Market size and forecast By Region
8.2. North America
8.2.1. Key market trends, growth factors and opportunities
8.2.2. Market size and forecast, by Product and Services
8.2.3. Market size and forecast, by Technique
8.2.4. Market size and forecast, by Application
8.2.5. Market size and forecast, by End User
8.2.6. Market size and forecast, by country
8.2.6.1. U.S.
8.2.6.1.1. Market size and forecast, by Product and Services
8.2.6.1.2. Market size and forecast, by Technique
8.2.6.1.3. Market size and forecast, by Application
8.2.6.1.4. Market size and forecast, by End User
8.2.6.2. Canada
8.2.6.2.1. Market size and forecast, by Product and Services
8.2.6.2.2. Market size and forecast, by Technique
8.2.6.2.3. Market size and forecast, by Application
8.2.6.2.4. Market size and forecast, by End User
8.2.6.3. Mexico
8.2.6.3.1. Market size and forecast, by Product and Services
8.2.6.3.2. Market size and forecast, by Technique
8.2.6.3.3. Market size and forecast, by Application
8.2.6.3.4. Market size and forecast, by End User
8.3. Europe
8.3.1. Key market trends, growth factors and opportunities
8.3.2. Market size and forecast, by Product and Services
8.3.3. Market size and forecast, by Technique
8.3.4. Market size and forecast, by Application
8.3.5. Market size and forecast, by End User
8.3.6. Market size and forecast, by country
8.3.6.1. Germany
8.3.6.1.1. Market size and forecast, by Product and Services
8.3.6.1.2. Market size and forecast, by Technique
8.3.6.1.3. Market size and forecast, by Application
8.3.6.1.4. Market size and forecast, by End User
8.3.6.2. France
8.3.6.2.1. Market size and forecast, by Product and Services
8.3.6.2.2. Market size and forecast, by Technique
8.3.6.2.3. Market size and forecast, by Application
8.3.6.2.4. Market size and forecast, by End User
8.3.6.3. UK
8.3.6.3.1. Market size and forecast, by Product and Services
8.3.6.3.2. Market size and forecast, by Technique
8.3.6.3.3. Market size and forecast, by Application
8.3.6.3.4. Market size and forecast, by End User
8.3.6.4. Italy
8.3.6.4.1. Market size and forecast, by Product and Services
8.3.6.4.2. Market size and forecast, by Technique
8.3.6.4.3. Market size and forecast, by Application
8.3.6.4.4. Market size and forecast, by End User
8.3.6.5. Spain
8.3.6.5.1. Market size and forecast, by Product and Services
8.3.6.5.2. Market size and forecast, by Technique
8.3.6.5.3. Market size and forecast, by Application
8.3.6.5.4. Market size and forecast, by End User
8.3.6.6. Rest of Europe
8.3.6.6.1. Market size and forecast, by Product and Services
8.3.6.6.2. Market size and forecast, by Technique
8.3.6.6.3. Market size and forecast, by Application
8.3.6.6.4. Market size and forecast, by End User
8.4. Asia-Pacific
8.4.1. Key market trends, growth factors and opportunities
8.4.2. Market size and forecast, by Product and Services
8.4.3. Market size and forecast, by Technique
8.4.4. Market size and forecast, by Application
8.4.5. Market size and forecast, by End User
8.4.6. Market size and forecast, by country
8.4.6.1. Japan
8.4.6.1.1. Market size and forecast, by Product and Services
8.4.6.1.2. Market size and forecast, by Technique
8.4.6.1.3. Market size and forecast, by Application
8.4.6.1.4. Market size and forecast, by End User
8.4.6.2. China
8.4.6.2.1. Market size and forecast, by Product and Services
8.4.6.2.2. Market size and forecast, by Technique
8.4.6.2.3. Market size and forecast, by Application
8.4.6.2.4. Market size and forecast, by End User
8.4.6.3. India
8.4.6.3.1. Market size and forecast, by Product and Services
8.4.6.3.2. Market size and forecast, by Technique
8.4.6.3.3. Market size and forecast, by Application
8.4.6.3.4. Market size and forecast, by End User
8.4.6.4. Australia
8.4.6.4.1. Market size and forecast, by Product and Services
8.4.6.4.2. Market size and forecast, by Technique
8.4.6.4.3. Market size and forecast, by Application
8.4.6.4.4. Market size and forecast, by End User
8.4.6.5. South Korea
8.4.6.5.1. Market size and forecast, by Product and Services
8.4.6.5.2. Market size and forecast, by Technique
8.4.6.5.3. Market size and forecast, by Application
8.4.6.5.4. Market size and forecast, by End User
8.4.6.6. Rest of Asia-Pacific
8.4.6.6.1. Market size and forecast, by Product and Services
8.4.6.6.2. Market size and forecast, by Technique
8.4.6.6.3. Market size and forecast, by Application
8.4.6.6.4. Market size and forecast, by End User
8.5. LAMEA
8.5.1. Key market trends, growth factors and opportunities
8.5.2. Market size and forecast, by Product and Services
8.5.3. Market size and forecast, by Technique
8.5.4. Market size and forecast, by Application
8.5.5. Market size and forecast, by End User
8.5.6. Market size and forecast, by country
8.5.6.1. Brazil
8.5.6.1.1. Market size and forecast, by Product and Services
8.5.6.1.2. Market size and forecast, by Technique
8.5.6.1.3. Market size and forecast, by Application
8.5.6.1.4. Market size and forecast, by End User
8.5.6.2. Saudi Arabia
8.5.6.2.1. Market size and forecast, by Product and Services
8.5.6.2.2. Market size and forecast, by Technique
8.5.6.2.3. Market size and forecast, by Application
8.5.6.2.4. Market size and forecast, by End User
8.5.6.3. South Africa
8.5.6.3.1. Market size and forecast, by Product and Services
8.5.6.3.2. Market size and forecast, by Technique
8.5.6.3.3. Market size and forecast, by Application
8.5.6.3.4. Market size and forecast, by End User
8.5.6.4. Rest of LAMEA
8.5.6.4.1. Market size and forecast, by Product and Services
8.5.6.4.2. Market size and forecast, by Technique
8.5.6.4.3. Market size and forecast, by Application
8.5.6.4.4. Market size and forecast, by End User
CHAPTER 9: COMPETITIVE LANDSCAPE
9.1. Introduction
9.2. Top winning strategies
9.3. Product mapping of top 10 player
9.4. Competitive dashboard
9.5. Competitive heatmap
9.6. Top player positioning, 2022
CHAPTER 10: COMPANY PROFILES
10.1. Freenome Holdings, Inc.
10.1.1. Company overview
10.1.2. Key executives
10.1.3. Company snapshot
10.1.4. Operating business segments
10.1.5. Product portfolio
10.1.6. Key strategic moves and developments
10.2. Natera, Inc.
10.2.1. Company overview
10.2.2. Key executives
10.2.3. Company snapshot
10.2.4. Operating business segments
10.2.5. Product portfolio
10.2.6. Business performance
10.2.7. Key strategic moves and developments
10.3. Agilent Technologies, Inc.
10.3.1. Company overview
10.3.2. Key executives
10.3.3. Company snapshot
10.3.4. Operating business segments
10.3.5. Product portfolio
10.3.6. Business performance
10.3.7. Key strategic moves and developments
10.4. Exact Sciences Corporation
10.4.1. Company overview
10.4.2. Key executives
10.4.3. Company snapshot
10.4.4. Operating business segments
10.4.5. Product portfolio
10.4.6. Business performance
10.4.7. Key strategic moves and developments
10.5. Illumina, Inc.
10.5.1. Company overview
10.5.2. Key executives
10.5.3. Company snapshot
10.5.4. Operating business segments
10.5.5. Product portfolio
10.5.6. Business performance
10.5.7. Key strategic moves and developments
10.6. F. Hoffmann-La Roche Ltd.
10.6.1. Company overview
10.6.2. Key executives
10.6.3. Company snapshot
10.6.4. Operating business segments
10.6.5. Product portfolio
10.6.6. Business performance
10.6.7. Key strategic moves and developments
10.7. Guardant Health
10.7.1. Company overview
10.7.2. Key executives
10.7.3. Company snapshot
10.7.4. Operating business segments
10.7.5. Product portfolio
10.7.6. Business performance
10.7.7. Key strategic moves and developments
10.8. InterVenn Biosciences
10.8.1. Company overview
10.8.2. Key executives
10.8.3. Company snapshot
10.8.4. Operating business segments
10.8.5. Product portfolio
10.8.6. Key strategic moves and developments
10.9. Thermo Fisher Scientific, Inc.
10.9.1. Company overview
10.9.2. Key executives
10.9.3. Company snapshot
10.9.4. Operating business segments
10.9.5. Product portfolio
10.9.6. Business performance
10.9.7. Key strategic moves and developments
10.10. Invitae Corporation
10.10.1. Company overview
10.10.2. Key executives
10.10.3. Company snapshot
10.10.4. Operating business segments
10.10.5. Product portfolio
10.10.6. Business performance
10.10.7. Key strategic moves and developments
10.11. NeoGenomics Laboratories
10.11.1. Company overview
10.11.2. Key executives
10.11.3. Company snapshot
10.11.4. Operating business segments
10.11.5. Product portfolio
10.11.6. Business performance
10.11.7. Key strategic moves and developments
LIST OF TABLES
TABLE 01. GLOBAL IN VITRO DIAGNOSTICS MARKET, BY PRODUCT AND SERVICES, 2022-2032 ($MILLION)
TABLE 02. IN VITRO DIAGNOSTICS MARKET FOR REAGENTS AND KITS, BY REGION, 2022-2032 ($MILLION)
TABLE 03. IN VITRO DIAGNOSTICS MARKET FOR INSTRUMENTS, BY REGION, 2022-2032 ($MILLION)
TABLE 04. IN VITRO DIAGNOSTICS MARKET FOR SOFTWARE AND SERVICES, BY REGION, 2022-2032 ($MILLION)
TABLE 05. GLOBAL IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
TABLE 06. IN VITRO DIAGNOSTICS MARKET FOR IMMUNODIAGNOSTICS, BY REGION, 2022-2032 ($MILLION)
TABLE 07. IN VITRO DIAGNOSTICS MARKET FOR HEMATOLOGY, BY REGION, 2022-2032 ($MILLION)
TABLE 08. IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY REGION, 2022-2032 ($MILLION)
TABLE 09. IN VITRO DIAGNOSTICS MARKET FOR TISSUE DIAGNOSTICS, BY REGION, 2022-2032 ($MILLION)
TABLE 10. IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY REGION, 2022-2032 ($MILLION)
TABLE 11. IN VITRO DIAGNOSTICS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 12. GLOBAL IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 13. IN VITRO DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2022-2032 ($MILLION)
TABLE 14. IN VITRO DIAGNOSTICS MARKET FOR CANCER, BY REGION, 2022-2032 ($MILLION)
TABLE 15. IN VITRO DIAGNOSTICS MARKET FOR CARDIAC DISEASES, BY REGION, 2022-2032 ($MILLION)
TABLE 16. IN VITRO DIAGNOSTICS MARKET FOR IMMUNE SYSTEM DISORDERS, BY REGION, 2022-2032 ($MILLION)
TABLE 17. IN VITRO DIAGNOSTICS MARKET FOR NEPHROLOGICAL DISEASES, BY REGION, 2022-2032 ($MILLION)
TABLE 18. IN VITRO DIAGNOSTICS MARKET FOR GASTROINTESTINAL DISEASES, BY REGION, 2022-2032 ($MILLION)
TABLE 19. IN VITRO DIAGNOSTICS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 20. GLOBAL IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 21. IN VITRO DIAGNOSTICS MARKET FOR STANDALONE LABORATORIES, BY REGION, 2022-2032 ($MILLION)
TABLE 22. IN VITRO DIAGNOSTICS MARKET FOR HOSPITALS, BY REGION, 2022-2032 ($MILLION)
TABLE 23. IN VITRO DIAGNOSTICS MARKET FOR ACADEMIC AND MEDICAL SCHOOLS, BY REGION, 2022-2032 ($MILLION)
TABLE 24. IN VITRO DIAGNOSTICS MARKET FOR POINT OF CARE, BY REGION, 2022-2032 ($MILLION)
TABLE 25. IN VITRO DIAGNOSTICS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 26. IN VITRO DIAGNOSTICS MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 27. NORTH AMERICA IN VITRO DIAGNOSTICS MARKET, BY PRODUCT AND SERVICES, 2022-2032 ($MILLION)
TABLE 28. NORTH AMERICA IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
TABLE 29. NORTH AMERICA IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 30. NORTH AMERICA IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 31. NORTH AMERICA IN VITRO DIAGNOSTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 32. U.S. IN VITRO DIAGNOSTICS MARKET, BY PRODUCT AND SERVICES, 2022-2032 ($MILLION)
TABLE 33. U.S. IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
TABLE 34. U.S. IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 35. U.S. IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 36. CANADA IN VITRO DIAGNOSTICS MARKET, BY PRODUCT AND SERVICES, 2022-2032 ($MILLION)
TABLE 37. CANADA IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
TABLE 38. CANADA IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 39. CANADA IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 40. MEXICO IN VITRO DIAGNOSTICS MARKET, BY PRODUCT AND SERVICES, 2022-2032 ($MILLION)
TABLE 41. MEXICO IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
TABLE 42. MEXICO IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 43. MEXICO IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 44. EUROPE IN VITRO DIAGNOSTICS MARKET, BY PRODUCT AND SERVICES, 2022-2032 ($MILLION)
TABLE 45. EUROPE IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
TABLE 46. EUROPE IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 47. EUROPE IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 48. EUROPE IN VITRO DIAGNOSTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 49. GERMANY IN VITRO DIAGNOSTICS MARKET, BY PRODUCT AND SERVICES, 2022-2032 ($MILLION)
TABLE 50. GERMANY IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
TABLE 51. GERMANY IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 52. GERMANY IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 53. FRANCE IN VITRO DIAGNOSTICS MARKET, BY PRODUCT AND SERVICES, 2022-2032 ($MILLION)
TABLE 54. FRANCE IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
TABLE 55. FRANCE IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 56. FRANCE IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 57. UK IN VITRO DIAGNOSTICS MARKET, BY PRODUCT AND SERVICES, 2022-2032 ($MILLION)
TABLE 58. UK IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
TABLE 59. UK IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 60. UK IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 61. ITALY IN VITRO DIAGNOSTICS MARKET, BY PRODUCT AND SERVICES, 2022-2032 ($MILLION)
TABLE 62. ITALY IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
TABLE 63. ITALY IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 64. ITALY IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 65. SPAIN IN VITRO DIAGNOSTICS MARKET, BY PRODUCT AND SERVICES, 2022-2032 ($MILLION)
TABLE 66. SPAIN IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
TABLE 67. SPAIN IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 68. SPAIN IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 69. REST OF EUROPE IN VITRO DIAGNOSTICS MARKET, BY PRODUCT AND SERVICES, 2022-2032 ($MILLION)
TABLE 70. REST OF EUROPE IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
TABLE 71. REST OF EUROPE IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 72. REST OF EUROPE IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 73. ASIA-PACIFIC IN VITRO DIAGNOSTICS MARKET, BY PRODUCT AND SERVICES, 2022-2032 ($MILLION)
TABLE 74. ASIA-PACIFIC IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
TABLE 75. ASIA-PACIFIC IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 76. ASIA-PACIFIC IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 77. ASIA-PACIFIC IN VITRO DIAGNOSTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 78. JAPAN IN VITRO DIAGNOSTICS MARKET, BY PRODUCT AND SERVICES, 2022-2032 ($MILLION)
TABLE 79. JAPAN IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
TABLE 80. JAPAN IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 81. JAPAN IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 82. CHINA IN VITRO DIAGNOSTICS MARKET, BY PRODUCT AND SERVICES, 2022-2032 ($MILLION)
TABLE 83. CHINA IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
TABLE 84. CHINA IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 85. CHINA IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 86. INDIA IN VITRO DIAGNOSTICS MARKET, BY PRODUCT AND SERVICES, 2022-2032 ($MILLION)
TABLE 87. INDIA IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
TABLE 88. INDIA IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 89. INDIA IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 90. AUSTRALIA IN VITRO DIAGNOSTICS MARKET, BY PRODUCT AND SERVICES, 2022-2032 ($MILLION)
TABLE 91. AUSTRALIA IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
TABLE 92. AUSTRALIA IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 93. AUSTRALIA IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 94. SOUTH KOREA IN VITRO DIAGNOSTICS MARKET, BY PRODUCT AND SERVICES, 2022-2032 ($MILLION)
TABLE 95. SOUTH KOREA IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
TABLE 96. SOUTH KOREA IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 97. SOUTH KOREA IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 98. REST OF ASIA-PACIFIC IN VITRO DIAGNOSTICS MARKET, BY PRODUCT AND SERVICES, 2022-2032 ($MILLION)
TABLE 99. REST OF ASIA-PACIFIC IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
TABLE 100. REST OF ASIA-PACIFIC IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 101. REST OF ASIA-PACIFIC IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 102. LAMEA IN VITRO DIAGNOSTICS MARKET, BY PRODUCT AND SERVICES, 2022-2032 ($MILLION)
TABLE 103. LAMEA IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
TABLE 104. LAMEA IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 105. LAMEA IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 106. LAMEA IN VITRO DIAGNOSTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 107. BRAZIL IN VITRO DIAGNOSTICS MARKET, BY PRODUCT AND SERVICES, 2022-2032 ($MILLION)
TABLE 108. BRAZIL IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
TABLE 109. BRAZIL IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 110. BRAZIL IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 111. SAUDI ARABIA IN VITRO DIAGNOSTICS MARKET, BY PRODUCT AND SERVICES, 2022-2032 ($MILLION)
TABLE 112. SAUDI ARABIA IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
TABLE 113. SAUDI ARABIA IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 114. SAUDI ARABIA IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 115. SOUTH AFRICA IN VITRO DIAGNOSTICS MARKET, BY PRODUCT AND SERVICES, 2022-2032 ($MILLION)
TABLE 116. SOUTH AFRICA IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
TABLE 117. SOUTH AFRICA IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 118. SOUTH AFRICA IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 119. REST OF LAMEA IN VITRO DIAGNOSTICS MARKET, BY PRODUCT AND SERVICES, 2022-2032 ($MILLION)
TABLE 120. REST OF LAMEA IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
TABLE 121. REST OF LAMEA IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 122. REST OF LAMEA IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 123. FREENOME HOLDINGS, INC.: KEY EXECUTIVES
TABLE 124. FREENOME HOLDINGS, INC.: COMPANY SNAPSHOT
TABLE 125. FREENOME HOLDINGS, INC.: PRODUCT SEGMENTS
TABLE 126. FREENOME HOLDINGS, INC.: PRODUCT PORTFOLIO
TABLE 127. FREENOME HOLDINGS, INC.: KEY STRATERGIES
TABLE 128. NATERA, INC.: KEY EXECUTIVES
TABLE 129. NATERA, INC.: COMPANY SNAPSHOT
TABLE 130. NATERA, INC.: PRODUCT SEGMENTS
TABLE 131. NATERA, INC.: PRODUCT PORTFOLIO
TABLE 132. NATERA, INC.: KEY STRATERGIES
TABLE 133. AGILENT TECHNOLOGIES, INC.: KEY EXECUTIVES
TABLE 134. AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT
TABLE 135. AGILENT TECHNOLOGIES, INC.: PRODUCT SEGMENTS
TABLE 136. AGILENT TECHNOLOGIES, INC.: PRODUCT PORTFOLIO
TABLE 137. AGILENT TECHNOLOGIES, INC.: KEY STRATERGIES
TABLE 138. EXACT SCIENCES CORPORATION: KEY EXECUTIVES
TABLE 139. EXACT SCIENCES CORPORATION: COMPANY SNAPSHOT
TABLE 140. EXACT SCIENCES CORPORATION: PRODUCT SEGMENTS
TABLE 141. EXACT SCIENCES CORPORATION: PRODUCT PORTFOLIO
TABLE 142. EXACT SCIENCES CORPORATION: KEY STRATERGIES
TABLE 143. ILLUMINA, INC.: KEY EXECUTIVES
TABLE 144. ILLUMINA, INC.: COMPANY SNAPSHOT
TABLE 145. ILLUMINA, INC.: PRODUCT SEGMENTS
TABLE 146. ILLUMINA, INC.: PRODUCT PORTFOLIO
TABLE 147. ILLUMINA, INC.: KEY STRATERGIES
TABLE 148. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
TABLE 149. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
TABLE 150. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS
TABLE 151. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
TABLE 152. F. HOFFMANN-LA ROCHE LTD.: KEY STRATERGIES
TABLE 153. GUARDANT HEALTH: KEY EXECUTIVES
TABLE 154. GUARDANT HEALTH: COMPANY SNAPSHOT
TABLE 155. GUARDANT HEALTH: PRODUCT SEGMENTS
TABLE 156. GUARDANT HEALTH: PRODUCT PORTFOLIO
TABLE 157. GUARDANT HEALTH: KEY STRATERGIES
TABLE 158. INTERVENN BIOSCIENCES: KEY EXECUTIVES
TABLE 159. INTERVENN BIOSCIENCES: COMPANY SNAPSHOT
TABLE 160. INTERVENN BIOSCIENCES: PRODUCT SEGMENTS
TABLE 161. INTERVENN BIOSCIENCES: PRODUCT PORTFOLIO
TABLE 162. INTERVENN BIOSCIENCES: KEY STRATERGIES
TABLE 163. THERMO FISHER SCIENTIFIC, INC.: KEY EXECUTIVES
TABLE 164. THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT
TABLE 165. THERMO FISHER SCIENTIFIC, INC.: PRODUCT SEGMENTS
TABLE 166. THERMO FISHER SCIENTIFIC, INC.: PRODUCT PORTFOLIO
TABLE 167. THERMO FISHER SCIENTIFIC, INC.: KEY STRATERGIES
TABLE 168. INVITAE CORPORATION: KEY EXECUTIVES
TABLE 169. INVITAE CORPORATION: COMPANY SNAPSHOT
TABLE 170. INVITAE CORPORATION: PRODUCT SEGMENTS
TABLE 171. INVITAE CORPORATION: PRODUCT PORTFOLIO
TABLE 172. INVITAE CORPORATION: KEY STRATERGIES
TABLE 173. NEOGENOMICS LABORATORIES: KEY EXECUTIVES
TABLE 174. NEOGENOMICS LABORATORIES: COMPANY SNAPSHOT
TABLE 175. NEOGENOMICS LABORATORIES: SERVICE SEGMENTS
TABLE 176. NEOGENOMICS LABORATORIES: PRODUCT PORTFOLIO
TABLE 177. NEOGENOMICS LABORATORIES: KEY STRATERGIES
LIST OF FIGURES
FIGURE 01. IN VITRO DIAGNOSTICS MARKET, 2022-2032
FIGURE 02. SEGMENTATION OF IN VITRO DIAGNOSTICS MARKET,2022-2032
FIGURE 03. TOP IMPACTING FACTORS IN IN VITRO DIAGNOSTICS MARKET
FIGURE 04. TOP INVESTMENT POCKETS IN IN VITRO DIAGNOSTICS MARKET (2023-2032)
FIGURE 05. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 06. MODERATE THREAT OF NEW ENTRANTS
FIGURE 07. MODERATE THREAT OF SUBSTITUTES
FIGURE 08. MODERATE INTENSITY OF RIVALRY
FIGURE 09. HIGH BARGAINING POWER OF BUYERS
FIGURE 10. GLOBAL IN VITRO DIAGNOSTICS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 11. IN VITRO DIAGNOSTICS MARKET, BY PRODUCT AND SERVICES, 2022 AND 2032(%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR REAGENTS AND KITS, BY COUNTRY 2022 AND 2032(%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY 2022 AND 2032(%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR SOFTWARE AND SERVICES, BY COUNTRY 2022 AND 2032(%)
FIGURE 15. IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2022 AND 2032(%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR IMMUNODIAGNOSTICS, BY COUNTRY 2022 AND 2032(%)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR HEMATOLOGY, BY COUNTRY 2022 AND 2032(%)
FIGURE 18. COMPARATIVE SHARE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY 2022 AND 2032(%)
FIGURE 19. COMPARATIVE SHARE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR TISSUE DIAGNOSTICS, BY COUNTRY 2022 AND 2032(%)
FIGURE 20. COMPARATIVE SHARE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY 2022 AND 2032(%)
FIGURE 21. COMPARATIVE SHARE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 22. IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022 AND 2032(%)
FIGURE 23. COMPARATIVE SHARE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY 2022 AND 2032(%)
FIGURE 24. COMPARATIVE SHARE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR CANCER, BY COUNTRY 2022 AND 2032(%)
FIGURE 25. COMPARATIVE SHARE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR CARDIAC DISEASES, BY COUNTRY 2022 AND 2032(%)
FIGURE 26. COMPARATIVE SHARE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR IMMUNE SYSTEM DISORDERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 27. COMPARATIVE SHARE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR NEPHROLOGICAL DISEASES, BY COUNTRY 2022 AND 2032(%)
FIGURE 28. COMPARATIVE SHARE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY 2022 AND 2032(%)
FIGURE 29. COMPARATIVE SHARE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 30. IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022 AND 2032(%)
FIGURE 31. COMPARATIVE SHARE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR STANDALONE LABORATORIES, BY COUNTRY 2022 AND 2032(%)
FIGURE 32. COMPARATIVE SHARE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR HOSPITALS, BY COUNTRY 2022 AND 2032(%)
FIGURE 33. COMPARATIVE SHARE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR ACADEMIC AND MEDICAL SCHOOLS, BY COUNTRY 2022 AND 2032(%)
FIGURE 34. COMPARATIVE SHARE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR POINT OF CARE, BY COUNTRY 2022 AND 2032(%)
FIGURE 35. COMPARATIVE SHARE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 36. IN VITRO DIAGNOSTICS MARKET BY REGION, 2022 AND 2032(%)
FIGURE 37. U.S. IN VITRO DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
FIGURE 38. CANADA IN VITRO DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
FIGURE 39. MEXICO IN VITRO DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
FIGURE 40. GERMANY IN VITRO DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
FIGURE 41. FRANCE IN VITRO DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
FIGURE 42. UK IN VITRO DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
FIGURE 43. ITALY IN VITRO DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
FIGURE 44. SPAIN IN VITRO DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
FIGURE 45. REST OF EUROPE IN VITRO DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
FIGURE 46. JAPAN IN VITRO DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
FIGURE 47. CHINA IN VITRO DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
FIGURE 48. INDIA IN VITRO DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
FIGURE 49. AUSTRALIA IN VITRO DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
FIGURE 50. SOUTH KOREA IN VITRO DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
FIGURE 51. REST OF ASIA-PACIFIC IN VITRO DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
FIGURE 52. BRAZIL IN VITRO DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
FIGURE 53. SAUDI ARABIA IN VITRO DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
FIGURE 54. SOUTH AFRICA IN VITRO DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
FIGURE 55. REST OF LAMEA IN VITRO DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
FIGURE 56. TOP WINNING STRATEGIES, BY YEAR (2020-2023)
FIGURE 57. TOP WINNING STRATEGIES, BY DEVELOPMENT (2020-2023)
FIGURE 58. TOP WINNING STRATEGIES, BY COMPANY (2020-2023)
FIGURE 59. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 60. COMPETITIVE DASHBOARD
FIGURE 61. COMPETITIVE HEATMAP: IN VITRO DIAGNOSTICS MARKET
FIGURE 62. TOP PLAYER POSITIONING, 2022
FIGURE 63. NATERA, INC.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 64. NATERA, INC.: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 65. AGILENT TECHNOLOGIES, INC.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 66. AGILENT TECHNOLOGIES, INC.: RESEARCH & DEVELOPMENT EXPENDITURE, 2020-2022 ($MILLION)
FIGURE 67. AGILENT TECHNOLOGIES, INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 68. AGILENT TECHNOLOGIES, INC.: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 69. EXACT SCIENCES CORPORATION: NET REVENUE, 2019-2021 ($MILLION)
FIGURE 70. EXACT SCIENCES CORPORATION: REVENUE SHARE BY REGION, 2021 (%)
FIGURE 71. ILLUMINA, INC.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 72. ILLUMINA, INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 73. ILLUMINA, INC.: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 74. F. HOFFMANN-LA ROCHE LTD.: SALES REVENUE, 2020-2022 ($MILLION)
FIGURE 75. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 76. GUARDANT HEALTH: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 77. GUARDANT HEALTH: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 78. THERMO FISHER SCIENTIFIC, INC.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 79. THERMO FISHER SCIENTIFIC, INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 80. THERMO FISHER SCIENTIFIC, INC.: REVENUE SHARE BY REGION, 2021 (%)
FIGURE 81. INVITAE CORPORATION: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 82. INVITAE CORPORATION: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 83. NEOGENOMICS LABORATORIES: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 84. NEOGENOMICS LABORATORIES: REVENUE SHARE BY SEGMENT, 2022 (%)
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security